Home blood pressure control status in 2017-2018 for hypertension specialist centers in Asia: Results of the Asia BP@Home study

HOPE Asia Network

doi:10.1111/jch.13415

Home blood pressure control status in 2017-2018 for hypertension specialist centers in Asia: Results of the Asia BP@Home study

HOPE Asia Network

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

34 Citations (Scopus)

Abstract

A self-measured home blood pressure (BP)-guided strategy is an effective practical approach to hypertension management. The Asia BP@Home study is the first designed to investigate current home BP control status in different Asian countries/regions using standardized home BP measurements taken with the same validated home BP monitoring device with data memory. We enrolled 1443 medicated hypertensive patients from 15 Asian specialist centers in 11 countries/regions between April 2017 and March 2018. BP was relatively well controlled in 68.2% of patients using a morning home systolic BP (SBP) cutoff of <135 mm Hg, and in 55.1% of patients using a clinic SBP cutoff of <140 mm Hg. When cutoff values were changed to the 2017 AHA/ACC threshold (SBP <130 mm Hg), 53.6% of patients were well controlled for morning home SBP. Using clinic 140 mm Hg and morning home 135 mm Hg SBP thresholds, the proportion of patients with well-controlled hypertension (46%) was higher than for uncontrolled sustained (22%), white-coat (23%), and masked uncontrolled (9%) hypertension, with significant country/regional differences. Home BP variability in Asian countries was high, and varied by country/region. In conclusion, the Asia BP@Home study demonstrated that home BP is relatively well controlled at hypertension specialist centers in Asia. However, almost half of patients remain uncontrolled for morning BP according to new guidelines, with significant country/regional differences. Strict home BP control should be beneficial in Asian populations. The findings of this study are important to facilitate development of health policies focused on reducing cardiovascular complications in Asia.

Original language	English
Pages (from-to)	1686-1695
Number of pages	10
Journal	Journal of Clinical Hypertension
Volume	20
Issue number	12
DOIs	https://doi.org/10.1111/jch.13415
Publication status	Published - 2018 Dec

Bibliographical note

Funding Information:
This study was supported by an Investigator Initiated Research grant from Pfizer, and Omron Healthcare who provided the use of com‐ puter servers to store study‐related data. The protocol for the study was developed by Jichi Medical University School of Medicine. Pfizer was not involved in the development of the protocol nor this manuscript. The authors acknowledge editorial support from Ayako Okura, editorial coordinator of Jichi Medical University School of Medicine, Japan. English language editing assistance was provided by Nicola Ryan, independent medical writer.

Funding Information:
CH Chen has received honoraria for serving as a speaker or mem‐ ber of a speaker bureau for AstraZeneca, Bayer AG, Boehringer Ingelheim, Bristol‐Myers Squibb, Daiichi Sankyo, Merck & Co, Novartis, Pfizer, Sanofi, Servier and Takeda. YC Chia has re‐ ceived honoraria for serving as a speaker or advisor for Abbott, Bayer, Boehringer Ingelheim, Merck, MSD, Novartis, Pfizer, Reckitt Benckiser, Sanofi, Servier and Takeda; sponsorship to scientific conferences from Pfizer and Takeda; and research grants from Pfizer. K Kario has received research grants from

Funding Information:
A&D Co., Bayer Yakuhin, Boehringer Ingelheim, Daiichi Sankyo, EA Pharma, Fukuda Denshi, Medtronic, Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Omron Healthcare, Otsuka, Pfizer, Takeda and Teijin Pharma; and hono‐ raria from Daiichi Sankyo, Omron Healthcare and Takeda. S Park has received honoraria from Astellas and Pfizer; and consulta‐ tion fees from Takeda. S Siddique has received honoraria from Bayer, Novartis, Pfizer, Sanofi Aventis and Servier; and travel, accommodation and conference registration support from Atco Pharmaceutical, Bayer, Highnoon Laboratories, Novartis, Pfizer, Sanofi Aventis and Servier. GP Sogunuru has received a research grant related to hypertension monitoring and treatment from Pfizer. All other authors report no potential conflict of interest in relation to this article.

All Science Journal Classification (ASJC) codes

Internal Medicine
Endocrinology, Diabetes and Metabolism
Cardiology and Cardiovascular Medicine

Access to Document

10.1111/jch.13415

Fingerprint Dive into the research topics of 'Home blood pressure control status in 2017-2018 for hypertension specialist centers in Asia: Results of the Asia BP@Home study'. Together they form a unique fingerprint.

Cite this

@article{9739ff042ceb488ea02a8d42d60d95ce,

title = "Home blood pressure control status in 2017-2018 for hypertension specialist centers in Asia: Results of the Asia BP@Home study",

abstract = "A self-measured home blood pressure (BP)-guided strategy is an effective practical approach to hypertension management. The Asia BP@Home study is the first designed to investigate current home BP control status in different Asian countries/regions using standardized home BP measurements taken with the same validated home BP monitoring device with data memory. We enrolled 1443 medicated hypertensive patients from 15 Asian specialist centers in 11 countries/regions between April 2017 and March 2018. BP was relatively well controlled in 68.2% of patients using a morning home systolic BP (SBP) cutoff of <135 mm Hg, and in 55.1% of patients using a clinic SBP cutoff of <140 mm Hg. When cutoff values were changed to the 2017 AHA/ACC threshold (SBP <130 mm Hg), 53.6% of patients were well controlled for morning home SBP. Using clinic 140 mm Hg and morning home 135 mm Hg SBP thresholds, the proportion of patients with well-controlled hypertension (46%) was higher than for uncontrolled sustained (22%), white-coat (23%), and masked uncontrolled (9%) hypertension, with significant country/regional differences. Home BP variability in Asian countries was high, and varied by country/region. In conclusion, the Asia BP@Home study demonstrated that home BP is relatively well controlled at hypertension specialist centers in Asia. However, almost half of patients remain uncontrolled for morning BP according to new guidelines, with significant country/regional differences. Strict home BP control should be beneficial in Asian populations. The findings of this study are important to facilitate development of health policies focused on reducing cardiovascular complications in Asia.",

author = "{HOPE Asia Network} and Kazuomi Kario and Naoko Tomitani and Peera Buranakitjaroen and Chia, {Yook Chin} and Sungha Park and Chen, {Chen Huan} and Romeo Divinagracia and Jinho Shin and Saulat Siddique and Jorge Sison and {Ann Soenarta}, Arieska and Sogunuru, {Guru Prasad} and Tay, {Jam Chin} and Yuda Turana and Yuqing Zhang and Jennifer Nailes and Sirisawat Wanthong and Satoshi Hoshide and Noriko Matsushita and Hiroshi Kanegae and Wang, {Ji Guang}",

note = "Funding Information: This study was supported by an Investigator Initiated Research grant from Pfizer, and Omron Healthcare who provided the use of com‐ puter servers to store study‐related data. The protocol for the study was developed by Jichi Medical University School of Medicine. Pfizer was not involved in the development of the protocol nor this manuscript. The authors acknowledge editorial support from Ayako Okura, editorial coordinator of Jichi Medical University School of Medicine, Japan. English language editing assistance was provided by Nicola Ryan, independent medical writer. Funding Information: CH Chen has received honoraria for serving as a speaker or mem‐ ber of a speaker bureau for AstraZeneca, Bayer AG, Boehringer Ingelheim, Bristol‐Myers Squibb, Daiichi Sankyo, Merck & Co, Novartis, Pfizer, Sanofi, Servier and Takeda. YC Chia has re‐ ceived honoraria for serving as a speaker or advisor for Abbott, Bayer, Boehringer Ingelheim, Merck, MSD, Novartis, Pfizer, Reckitt Benckiser, Sanofi, Servier and Takeda; sponsorship to scientific conferences from Pfizer and Takeda; and research grants from Pfizer. K Kario has received research grants from Funding Information: A&D Co., Bayer Yakuhin, Boehringer Ingelheim, Daiichi Sankyo, EA Pharma, Fukuda Denshi, Medtronic, Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Omron Healthcare, Otsuka, Pfizer, Takeda and Teijin Pharma; and hono‐ raria from Daiichi Sankyo, Omron Healthcare and Takeda. S Park has received honoraria from Astellas and Pfizer; and consulta‐ tion fees from Takeda. S Siddique has received honoraria from Bayer, Novartis, Pfizer, Sanofi Aventis and Servier; and travel, accommodation and conference registration support from Atco Pharmaceutical, Bayer, Highnoon Laboratories, Novartis, Pfizer, Sanofi Aventis and Servier. GP Sogunuru has received a research grant related to hypertension monitoring and treatment from Pfizer. All other authors report no potential conflict of interest in relation to this article.",

year = "2018",

month = dec,

doi = "10.1111/jch.13415",

language = "English",

volume = "20",

pages = "1686--1695",

journal = "Journal of Clinical Hypertension",

issn = "1524-6175",

publisher = "Wiley-Blackwell",

number = "12",

}

TY - JOUR

T1 - Home blood pressure control status in 2017-2018 for hypertension specialist centers in Asia

T2 - Results of the Asia BP@Home study

AU - HOPE Asia Network

AU - Kario, Kazuomi

AU - Tomitani, Naoko

AU - Buranakitjaroen, Peera

AU - Chia, Yook Chin

AU - Park, Sungha

AU - Chen, Chen Huan

AU - Divinagracia, Romeo

AU - Shin, Jinho

AU - Siddique, Saulat

AU - Sison, Jorge

AU - Ann Soenarta, Arieska

AU - Sogunuru, Guru Prasad

AU - Tay, Jam Chin

AU - Turana, Yuda

AU - Zhang, Yuqing

AU - Nailes, Jennifer

AU - Wanthong, Sirisawat

AU - Hoshide, Satoshi

AU - Matsushita, Noriko

AU - Kanegae, Hiroshi

AU - Wang, Ji Guang

N1 - Funding Information: This study was supported by an Investigator Initiated Research grant from Pfizer, and Omron Healthcare who provided the use of com‐ puter servers to store study‐related data. The protocol for the study was developed by Jichi Medical University School of Medicine. Pfizer was not involved in the development of the protocol nor this manuscript. The authors acknowledge editorial support from Ayako Okura, editorial coordinator of Jichi Medical University School of Medicine, Japan. English language editing assistance was provided by Nicola Ryan, independent medical writer. Funding Information: CH Chen has received honoraria for serving as a speaker or mem‐ ber of a speaker bureau for AstraZeneca, Bayer AG, Boehringer Ingelheim, Bristol‐Myers Squibb, Daiichi Sankyo, Merck & Co, Novartis, Pfizer, Sanofi, Servier and Takeda. YC Chia has re‐ ceived honoraria for serving as a speaker or advisor for Abbott, Bayer, Boehringer Ingelheim, Merck, MSD, Novartis, Pfizer, Reckitt Benckiser, Sanofi, Servier and Takeda; sponsorship to scientific conferences from Pfizer and Takeda; and research grants from Pfizer. K Kario has received research grants from Funding Information: A&D Co., Bayer Yakuhin, Boehringer Ingelheim, Daiichi Sankyo, EA Pharma, Fukuda Denshi, Medtronic, Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Omron Healthcare, Otsuka, Pfizer, Takeda and Teijin Pharma; and hono‐ raria from Daiichi Sankyo, Omron Healthcare and Takeda. S Park has received honoraria from Astellas and Pfizer; and consulta‐ tion fees from Takeda. S Siddique has received honoraria from Bayer, Novartis, Pfizer, Sanofi Aventis and Servier; and travel, accommodation and conference registration support from Atco Pharmaceutical, Bayer, Highnoon Laboratories, Novartis, Pfizer, Sanofi Aventis and Servier. GP Sogunuru has received a research grant related to hypertension monitoring and treatment from Pfizer. All other authors report no potential conflict of interest in relation to this article.

PY - 2018/12

Y1 - 2018/12

N2 - A self-measured home blood pressure (BP)-guided strategy is an effective practical approach to hypertension management. The Asia BP@Home study is the first designed to investigate current home BP control status in different Asian countries/regions using standardized home BP measurements taken with the same validated home BP monitoring device with data memory. We enrolled 1443 medicated hypertensive patients from 15 Asian specialist centers in 11 countries/regions between April 2017 and March 2018. BP was relatively well controlled in 68.2% of patients using a morning home systolic BP (SBP) cutoff of <135 mm Hg, and in 55.1% of patients using a clinic SBP cutoff of <140 mm Hg. When cutoff values were changed to the 2017 AHA/ACC threshold (SBP <130 mm Hg), 53.6% of patients were well controlled for morning home SBP. Using clinic 140 mm Hg and morning home 135 mm Hg SBP thresholds, the proportion of patients with well-controlled hypertension (46%) was higher than for uncontrolled sustained (22%), white-coat (23%), and masked uncontrolled (9%) hypertension, with significant country/regional differences. Home BP variability in Asian countries was high, and varied by country/region. In conclusion, the Asia BP@Home study demonstrated that home BP is relatively well controlled at hypertension specialist centers in Asia. However, almost half of patients remain uncontrolled for morning BP according to new guidelines, with significant country/regional differences. Strict home BP control should be beneficial in Asian populations. The findings of this study are important to facilitate development of health policies focused on reducing cardiovascular complications in Asia.

AB - A self-measured home blood pressure (BP)-guided strategy is an effective practical approach to hypertension management. The Asia BP@Home study is the first designed to investigate current home BP control status in different Asian countries/regions using standardized home BP measurements taken with the same validated home BP monitoring device with data memory. We enrolled 1443 medicated hypertensive patients from 15 Asian specialist centers in 11 countries/regions between April 2017 and March 2018. BP was relatively well controlled in 68.2% of patients using a morning home systolic BP (SBP) cutoff of <135 mm Hg, and in 55.1% of patients using a clinic SBP cutoff of <140 mm Hg. When cutoff values were changed to the 2017 AHA/ACC threshold (SBP <130 mm Hg), 53.6% of patients were well controlled for morning home SBP. Using clinic 140 mm Hg and morning home 135 mm Hg SBP thresholds, the proportion of patients with well-controlled hypertension (46%) was higher than for uncontrolled sustained (22%), white-coat (23%), and masked uncontrolled (9%) hypertension, with significant country/regional differences. Home BP variability in Asian countries was high, and varied by country/region. In conclusion, the Asia BP@Home study demonstrated that home BP is relatively well controlled at hypertension specialist centers in Asia. However, almost half of patients remain uncontrolled for morning BP according to new guidelines, with significant country/regional differences. Strict home BP control should be beneficial in Asian populations. The findings of this study are important to facilitate development of health policies focused on reducing cardiovascular complications in Asia.

UR - http://www.scopus.com/inward/record.url?scp=85056663634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056663634&partnerID=8YFLogxK

U2 - 10.1111/jch.13415

DO - 10.1111/jch.13415

M3 - Article

C2 - 30444315

AN - SCOPUS:85056663634

VL - 20

SP - 1686

EP - 1695

JO - Journal of Clinical Hypertension

JF - Journal of Clinical Hypertension

SN - 1524-6175

IS - 12

ER -